MSD (known as Merck & Co Inc. in the United States and Canada) has announced results from the randomised, pivotal Phase 3 study, KEYNOTE-006 which compared pembrolizumab to ipilimumab in patients...
Scientists from the Goethe University Frankfurt, the European Molecular Biology Laboratory Heidelberg and the University of Zurich explain skin fusion at a molecular level and pinpoint the specific...
Researchers have identified two drugs - an antifungal and a steroid - that reversed MS in mouse models of the condition by stimulating stem cells to boost myelin production.
Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment...
A skin cell responsible for scarring, and a molecule that inhibits the cell's activity, have been identified by researchers at the Stanford University School of Medicine.
Cellmid Limited has received strong positive results in all measured areas of its independently conducted, randomized, blinded and placebo controlled human clinical study of the évolis ONE...
Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international FDA...
We look at the main causes of hair loss in women, the emotional impact it can have and why research into new treatments for female hair loss appears to have been lagging.